RCUS · Arcus Biosciences, Inc.
AI read · Good for RCUS
The AI's read
That gives investors a more favorable outside view of Arcus. But it is an analyst's opinion, not new proof that the company's cancer treatments work.
Wedbush raised its target price for Arcus Biosciences to $49 from $43 and still thinks it will do well.
Good for RCUS
Wedbush raised its target and kept its Outperform rating, a favorable outside view for Arcus shares. The story reports no new trial results, so it does not show that Arcus's treatments work.
Get alerts for RCUS
Follow Arcus Biosciences, Inc. (RCUS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RCUSFree on the App Store and Google Play, or on the web.